However, in light of the barely improved overall survival of patients suffering from high grade gliomas besides maximal multimodal treatment, BRAF mutated subgroups remain interesting entities that need to be further assessed for their accessibility to specific treatment modalities. The gene discussed is BRAF; the disease is central nervous system cancer.